Jump to content

Vanderbilt-Ingram Cancer Center testing new lung cancer


Recommended Posts


http://nashville.bizjournals.com/nashvi ... ily36.html

Researchers at the Vanderbilt-Ingram Cancer Center are enrolling patients for a study involving a treatment of cancerous lesions in lungs.

The study will look at the effects of the investigational drug Iloprost, which is used to treat pulmonary hypertension and peripheral vascular disease, which are unrelated to lung cancer. In animal studies, the drug was shown to prevent lung cancer from developing, according to a statement announcing the study.

Dr. Pierre Massion, assistant professor of medicine in the division of allergy, pulmonary and critical care medicine at the Vanderbilt-Ingram Cancer Center, is enrolling participants who are current or former smokers, who (have) smoked a pack of cigarettes a day for more than 20 years or two packs a day for 10 years. Participants must be adults who have not been diagnosed with lung cancer.

"It's the No. 1 cancer killer in both men and women. You really have to approach the disease before it is there," said Massion through the statement. Most lung cancer is found too late to offer much chance of a cure. The five year-survival rate is around 15 percent.

Participants in the study will be given a placebo or Iloprost. The study is a double-blind trial, so Massion, his research nurse and participants won't know who is getting the actual drug.

Vanderbilt-Ingram Cancer Center is affiliated with Vanderbilt University Medical Center.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use. We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.